AU2020213978A1 - Treatment of skin lesions and pruritus in prurigo nodularis patients - Google Patents

Treatment of skin lesions and pruritus in prurigo nodularis patients Download PDF

Info

Publication number
AU2020213978A1
AU2020213978A1 AU2020213978A AU2020213978A AU2020213978A1 AU 2020213978 A1 AU2020213978 A1 AU 2020213978A1 AU 2020213978 A AU2020213978 A AU 2020213978A AU 2020213978 A AU2020213978 A AU 2020213978A AU 2020213978 A1 AU2020213978 A1 AU 2020213978A1
Authority
AU
Australia
Prior art keywords
nemolizumab
subject
pruritus
equivalent
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020213978A
Other languages
English (en)
Inventor
Christophe Piketty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Holding SA
Chugai Pharmaceutical Co Ltd
Original Assignee
Galderma Holding SA
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Holding SA, Chugai Pharmaceutical Co Ltd filed Critical Galderma Holding SA
Publication of AU2020213978A1 publication Critical patent/AU2020213978A1/en
Priority to AU2025263803A priority Critical patent/AU2025263803A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2020213978A 2019-01-28 2020-01-28 Treatment of skin lesions and pruritus in prurigo nodularis patients Abandoned AU2020213978A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025263803A AU2025263803A1 (en) 2019-01-28 2025-11-06 Treatment of skin lesions and pruritus in prurigo nodularis patients

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962797803P 2019-01-28 2019-01-28
US62/797,803 2019-01-28
US201962809404P 2019-02-22 2019-02-22
US62/809,404 2019-02-22
PCT/IB2020/050623 WO2020157636A1 (en) 2019-01-28 2020-01-28 Treatment of skin lesions and pruritus in prurigo nodularis patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025263803A Division AU2025263803A1 (en) 2019-01-28 2025-11-06 Treatment of skin lesions and pruritus in prurigo nodularis patients

Publications (1)

Publication Number Publication Date
AU2020213978A1 true AU2020213978A1 (en) 2021-09-23

Family

ID=69467604

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020213978A Abandoned AU2020213978A1 (en) 2019-01-28 2020-01-28 Treatment of skin lesions and pruritus in prurigo nodularis patients
AU2025263803A Pending AU2025263803A1 (en) 2019-01-28 2025-11-06 Treatment of skin lesions and pruritus in prurigo nodularis patients

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025263803A Pending AU2025263803A1 (en) 2019-01-28 2025-11-06 Treatment of skin lesions and pruritus in prurigo nodularis patients

Country Status (15)

Country Link
US (2) US11236157B2 (https=)
EP (1) EP3917617A1 (https=)
JP (4) JP7410852B2 (https=)
KR (1) KR102953189B1 (https=)
CN (1) CN113660981A (https=)
AU (2) AU2020213978A1 (https=)
BR (1) BR112021014854A2 (https=)
CA (1) CA3127983A1 (https=)
CL (1) CL2021001976A1 (https=)
IL (1) IL285171B2 (https=)
MX (1) MX2021009051A (https=)
PH (1) PH12021551805A1 (https=)
SG (1) SG11202108220YA (https=)
TW (1) TWI861052B (https=)
WO (1) WO2020157636A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021359068A1 (en) * 2020-10-15 2023-06-15 Intervet International B.V. Caninized antibodies to canine interleukin-31 receptor alpha
US20220411518A1 (en) * 2021-04-07 2022-12-29 Galderma Holding S.A. Treatments for prurigo nodularis
WO2023044313A1 (en) * 2021-09-15 2023-03-23 Dermira, Inc. Il-13 inhibitors for the treatment of prurigo nodularis
US20240141050A1 (en) * 2022-09-02 2024-05-02 Galderma Holding S.A. Treatments for prurigo nodularis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
ATE455852T1 (de) 1999-06-02 2010-02-15 Chugai Pharmaceutical Co Ltd Neues hämopoietin rezeptorprotein nr10
US20120220948A1 (en) 2008-04-18 2012-08-30 Ipsyrng Capital Development, Llc Ergonomic syringe
DE102007056240A1 (de) 2007-11-22 2009-05-28 Henke-Sass, Wolf Gmbh Spritze
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
CA3199034C (en) 2015-08-24 2025-09-09 Dmk Pharmaceuticals Corporation SYRINGE-TYPE DEVICES
KR101900427B1 (ko) 2018-05-25 2018-09-20 송향숙 가압력 측정이 가능한 주사기용 보조그립

Also Published As

Publication number Publication date
JP7410852B2 (ja) 2024-01-10
PH12021551805A1 (en) 2022-07-18
JP2022028788A (ja) 2022-02-16
JP2023182834A (ja) 2023-12-26
TW202043282A (zh) 2020-12-01
MX2021009051A (es) 2021-12-10
JP2021509103A (ja) 2021-03-18
CA3127983A1 (en) 2020-08-06
JP2023126909A (ja) 2023-09-12
KR102953189B1 (ko) 2026-04-15
US20220177568A1 (en) 2022-06-09
JP7671822B2 (ja) 2025-05-02
CL2021001976A1 (es) 2022-02-11
US20200239563A1 (en) 2020-07-30
IL285171B1 (en) 2025-11-01
TWI861052B (zh) 2024-11-11
JP7375252B2 (ja) 2023-11-07
WO2020157636A1 (en) 2020-08-06
US11236157B2 (en) 2022-02-01
CN113660981A (zh) 2021-11-16
KR20210122286A (ko) 2021-10-08
BR112021014854A2 (pt) 2021-12-21
IL285171B2 (en) 2026-03-01
IL285171A (en) 2021-09-30
AU2025263803A1 (en) 2025-11-27
SG11202108220YA (en) 2021-08-30
JP7309816B2 (ja) 2023-07-18
EP3917617A1 (en) 2021-12-08

Similar Documents

Publication Publication Date Title
JP7671822B2 (ja) 結節性痒疹患者における皮膚病変およびそう痒の治療
CN112689512B (zh) 用于治疗银屑病的组合物和方法
US20260008859A1 (en) Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
US20250011417A1 (en) Methods for the treatment of thyroid eye disease
RU2822134C2 (ru) Лечение поражений кожи и зуда у пациентов с узловатой почесухой
KR20260057215A (ko) 결절성 양진 환자에서 피부 병변 및 소양증의 치료
HK40130865A (en) Treatment of atopic dermatitis with moderate to severe excoriation
WO2025106642A1 (en) Methods for the treatment of thyroid eye disease
WO2024222891A1 (zh) 用重组白介素23p19抗体治疗银屑病的方法
HK40042731B (en) Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
HK40042731A (en) Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted